Caplin Point Laboratories Limited
NSE: CAPLIPOINT
NSE
1,723.00
-13.00 (-0.75%)
Prev Close
1736
Open Price
1730
Volume
65,701
Today Low / High
1709.6 / 1748.6
52 WK Low / High
1599 / 2395
Range
1,637 - 1,809
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 1723, with a change of -13 (-0.74885%). The expected target range on the NSE is between 1,637 - 1,809. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
23 Jan
1,730.00
-0.40%
22 Jan
1,731.00
0.29%
21 Jan
1,766.00
-1.52%
20 Jan
1,800.10
-0.97%
19 Jan
1,820.20
-0.44%
16 Jan
1,833.00
-0.37%
14 Jan
1,810.00
2.46%
13 Jan
1,812.40
-0.02%
12 Jan
1,810.50
-0.39%
09 Jan
1,804.00
0.53%
08 Jan
1,856.60
-2.03%
07 Jan
1,831.20
1.39%
06 Jan
1,839.00
-0.04%
05 Jan
1,837.00
0.45%
02 Jan
1,811.00
2.09%
01 Jan
1,840.10
-2.24%
31 Dec
1,785.80
2.93%
30 Dec
1,882.00
-4.85%
29 Dec
1,910.00
-0.86%
Caplin Point Laboratories Limited Graph
Caplin Point Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Caplin Point Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,723.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,723.00 | 1,740.23 | 1,566.21 - 1,914.25 |
| 1,757.46 | 1,405.97 - 2,108.95 | ||
| 1,774.69 | 1,242.28 - 2,307.10 | ||
| Bearish Scenario | 1,723.00 | 1,705.77 | 1,535.19 - 1,876.35 |
| 1,688.54 | 1,350.83 - 2,026.25 | ||
| 1,671.31 | 1,169.92 - 2,172.70 |
Overview of Caplin Point Laboratories Limited
ISIN
INE475E01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
63,523
Market Cap
130,968,152,208
Last Dividend
6
Official Website
IPO Date
2014-06-23
DCF Diff
-3,094.27
DCF
4,817
Financial Ratios Every Investor Needs
Stock Dividend of CAPLIPOINT
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-12 | September 12, 25 | 3 | 3 | 2025-09-12 | 2025-10-21 | |
| 2025-05-30 | May 30, 25 | 3 | 3 | 2025-05-30 | 2025-06-14 | |
| 2024-09-23 | September 23, 24 | 2.5 | 2.5 | 2024-09-23 | 2024-10-30 | |
| 2024-05-31 | May 31, 24 | 2.5 | 2.5 | 2024-05-31 | 2024-06-15 | |
| 2023-09-14 | September 14, 23 | 2.5 | 2.5 | 2023-09-14 | 2023-10-21 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,939.57 Cr | 801.66 Cr | 1,137.91 Cr | 0.5867 | 76.68 Cr | 0.00 Cr | 883.37 Cr | 536.31 Cr | 70.57 | 648.66 Cr | 0.2765 |
| 2024-03-31 | 1,696.11 Cr | 756.13 Cr | 939.98 Cr | 0.5542 | 73.72 Cr | 0.00 Cr | 722.53 Cr | 457.09 Cr | 60.19 | 550.65 Cr | 0.2695 |
| 2023-03-31 | 1,468.32 Cr | 679.19 Cr | 789.13 Cr | 0.5374 | 63.19 Cr | 0.00 Cr | 588.81 Cr | 376.26 Cr | 49.62 | 439.94 Cr | 0.2563 |
| 2022-03-31 | 1,270.95 Cr | 572.39 Cr | 698.56 Cr | 0.5496 | 59.27 Cr | 0.00 Cr | 523.85 Cr | 299.84 Cr | 39.61 | 393.85 Cr | 0.2359 |
| 2021-03-31 | 1,062.35 Cr | 480.63 Cr | 581.72 Cr | 0.5476 | 53.69 Cr | 0.00 Cr | 425.41 Cr | 242.27 Cr | 32.03 | 328.48 Cr | 0.2281 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 591.41 Cr | 3,208.58 Cr | 322.19 Cr | 2,850.4900 Cr | 5.02 Cr | -586.39 Cr | 336.10 Cr | 673.73 Cr | 0.00 Cr | 0.00 Cr | 279.13 Cr | 306.3800 Cr |
| 2024-03-31 | 550.12 Cr | 2,698.12 Cr | 351.29 Cr | 2,315.7100 Cr | 1.97 Cr | -548.15 Cr | 363.04 Cr | 556.76 Cr | 30.81 Cr | 10.48 Cr | 150.24 Cr | 331.2800 Cr |
| 2023-03-31 | 177.56 Cr | 2,191.40 Cr | 284.13 Cr | 1,880.4800 Cr | 5.48 Cr | -172.36 Cr | 288.22 Cr | 489.35 Cr | 22.53 Cr | -14.14 Cr | -472.31 Cr | 268.0000 Cr |
| 2022-03-31 | 456.74 Cr | 1,736.32 Cr | 226.44 Cr | 1,483.9300 Cr | 2.13 Cr | -454.61 Cr | 227.31 Cr | 293.43 Cr | 5.49 Cr | -21.79 Cr | 62.09 Cr | 207.6800 Cr |
| 2021-03-31 | 456.96 Cr | 1,363.61 Cr | 160.25 Cr | 1,185.8216 Cr | 18.39 Cr | -438.57 Cr | 179.00 Cr | 311.93 Cr | 33.20 Cr | 5.70 Cr | -9.87 Cr | 142.8535 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 432.3700 Cr | -334.7300 Cr | -38.3200 Cr | 240.8500 Cr | 60.7500 Cr | 199.4500 Cr | -191.5200 Cr | 536.3100 Cr | 0.2700 Cr | -37.9900 Cr | 26.9400 Cr |
| 2024-03-31 | 318.3900 Cr | -320.0400 Cr | -38.0700 Cr | 172.5700 Cr | -38.8600 Cr | 138.7000 Cr | -145.8200 Cr | 457.0900 Cr | -3.1300 Cr | -34.1700 Cr | -74.8200 Cr |
| 2023-03-31 | 271.6500 Cr | -217.8600 Cr | -28.1700 Cr | 77.9000 Cr | 26.8000 Cr | 177.5600 Cr | -193.7500 Cr | 451.3500 Cr | 2.9100 Cr | -30.3200 Cr | -60.9000 Cr |
| 2022-03-31 | 336.7500 Cr | -376.7700 Cr | -40.7100 Cr | 245.5700 Cr | -80.8100 Cr | 452.5000 Cr | -91.1800 Cr | 385.8200 Cr | -16.5600 Cr | -22.6900 Cr | -48.3100 Cr |
| 2021-03-31 | 268.6100 Cr | -29.4400 Cr | -23.9776 Cr | 195.2894 Cr | 214.9531 Cr | 452.3557 Cr | -70.4831 Cr | 313.6185 Cr | -19.4111 Cr | -3.0257 Cr | 59.2298 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 534.04 Cr | 275.93 Cr | 258.11 Cr | 0.4833 | 170.77 Cr | 154.45 Cr | 20.32 | 219.54 Cr | 0.2892 |
| 2025-06-30 | 510.22 Cr | 195.24 Cr | 314.98 Cr | 0.6173 | 253.86 Cr | 152.80 Cr | 20.10 | 177.96 Cr | 0.2995 |
| 2025-03-31 | 504.55 Cr | 232.02 Cr | 272.53 Cr | 0.5401 | 206.20 Cr | 142.57 Cr | 18.75 | 172.48 Cr | 0.2826 |
| 2024-12-31 | 492.96 Cr | 195.35 Cr | 297.61 Cr | 0.6037 | 232.68 Cr | 138.96 Cr | 18.28 | 158.52 Cr | 0.2819 |
| 2024-09-30 | 483.10 Cr | 188.82 Cr | 294.28 Cr | 0.6091 | 230.35 Cr | 130.80 Cr | 17.22 | 164.36 Cr | 0.2708 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 647.09 Cr | 370.11 Cr | 1,017.20 Cr | 694.45 Cr | 329.43 Cr | 2,328.12 Cr | 705.06 Cr | 3,503.92 Cr | 304.93 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 902.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,886.39 Cr |
| 2025-03-31 | 591.41 Cr | 311.33 Cr | 902.74 Cr | 632.49 Cr | 336.10 Cr | 2,133.95 Cr | 673.73 Cr | 3,208.58 Cr | 322.19 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 826.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,574.60 Cr |
| 2024-09-30 | 534.21 Cr | 292.41 Cr | 826.62 Cr | 617.98 Cr | 327.09 Cr | 1,998.82 Cr | 606.47 Cr | 2,924.22 Cr | 349.62 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 152.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 142.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 138.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 130.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 123.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2016-10-19 | October 19, 16 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,631.90 | ₹3,915,474,737,543.00 | ₹1,678,650.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,011.50 | ₹1,595,864,368,670.00 | ₹460,453.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,932.20 | ₹1,330,835,159,168.00 | ₹315,832.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,235.60 | ₹1,028,721,212,318.00 | ₹3,888,844.00 |
| Lupin Limited | LUPIN | ₹2,137.20 | ₹976,270,408,183.00 | ₹578,346.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹882.00 | ₹887,498,379,180.00 | ₹460,318.00 |
| Mankind Pharma Limited | MANKIND | ₹2,107.60 | ₹870,027,969,747.00 | ₹406,697.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,750.50 | ₹687,558,532,500.00 | ₹77,302.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,132.50 | ₹657,757,838,048.00 | ₹511,822.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,967.70 | ₹555,286,531,869.00 | ₹424,174.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,016.40 | ₹548,710,229,945.00 | ₹4,200,664.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,462.80 | ₹371,118,530,090.00 | ₹47,635.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,699.60 | ₹337,276,210,550.00 | ₹73,196.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,530.80 | ₹290,197,644,232.00 | ₹138,093.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,846.00 | ₹289,177,746,000.00 | ₹132,465.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,351.60 | ₹219,624,415,620.00 | ₹259,357.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,319.00 | ₹207,975,000,000.00 | ₹5,165.00 |
| Eris Lifesciences Limited | ERIS | ₹1,385.60 | ₹188,742,124,170.00 | ₹94,274.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,251.00 | ₹170,008,859,139.00 | ₹26,149.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹956.10 | ₹151,417,316,063.00 | ₹139,597.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹764.55 | ₹150,282,336,454.00 | ₹22,821.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹831.95 | ₹149,010,456,347.00 | ₹318,008.00 |
| Cohance Lifesciences Limited | COHANCE | ₹381.60 | ₹145,987,620,624.00 | ₹380,203.00 |
| Granules India Limited | GRANULES | ₹565.00 | ₹137,107,824,540.00 | ₹972,146.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,723.00 | ₹130,968,152,208.00 | ₹65,701.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹883.50 | ₹108,388,663,500.00 | ₹208,914.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,395.50 | ₹89,561,965,581.00 | ₹32,077.00 |
| Strides Pharma Science Limited | STAR | ₹796.25 | ₹73,392,523,523.00 | ₹356,395.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹768.70 | ₹69,680,574,898.00 | ₹277,301.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹424.80 | ₹65,037,754,238.00 | ₹81,217.00 |
| FDC Limited | FDC | ₹369.60 | ₹60,174,607,046.00 | ₹49,065.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹267.00 | ₹52,220,344,872.00 | ₹242,372.00 |
| Sequent Scientific Limited | SEQUENT | ₹201.37 | ₹50,307,022,432.00 | ₹364,240.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.94 | ₹40,545,727,205.00 | ₹476,606.00 |
| Innova Captab Limited | INNOVACAP | ₹678.05 | ₹38,801,363,108.00 | ₹1,793,841.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,135.70 | ₹35,322,374,336.00 | ₹4,017.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹688.40 | ₹34,915,031,882.00 | ₹42,892.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹317.80 | ₹34,629,161,217.00 | ₹174,725.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹370.05 | ₹33,774,463,500.00 | ₹102,103.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹309.70 | ₹31,057,492,108.00 | ₹32,969.00 |
| Suven Life Sciences Limited | SUVEN | ₹134.07 | ₹30,497,439,180.00 | ₹248,500.00 |
Key Executives
President - API R&D - Hyderabad
Neelakandan K.
Gender: Not Specified
Year Born: 1981
President of Clinical Research Operations
S. Gunasakaran
Gender: Not Specified
Year Born:
MD & Whole Time Director
Sridhar Ganesan
Gender: Not Specified
Year Born: 1955
Head of Marketing - Latam Business
Ashok Gorekey Partheeban
Gender: male
Year Born:
Chief Financial Officer - Finance & Accounts
D. Muralidharan
Gender: male
Year Born: 1956
Deputy Chief Financial Officer
Sathya Narayanan
Gender: male
Year Born:
General Counsel, Company Secretary & Compliance Officer
Venkatram Ganapathisu Bramanian
Gender: male
Year Born: 1982
Functional Head - HO, Production Planning & Inventory Control
R. Dinesh
Gender: Not Specified
Year Born:
Vice President
Sathish Krishnan
Gender: Not Specified
Year Born: 1978
Plant Head - Puducherry
Sivakumar Balasubramanian
Gender: Not Specified
Year Born: 1981
Functional Head -HO, HR & Admin
Anto Vijinth V.
Gender: Not Specified
Year Born:
FAQs about Caplin Point Laboratories Limited
Who is the CEO of the company?
The CEO is Sridhar Ganesan.
What is the current market price of the stock?
The current price is ₹1,723.00.
What is the 52-week price range?
The range is ₹1599-2395.
What is the market capitalization of the company?
The market capitalization is ₹13,096.82 crores.
What is the dividend yield?
The dividend yield is 0.35%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 22.24.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Caplin Point Laboratories Limited (ISIN: INE475E01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹13,096.82 crores and an average daily volume of 63,523 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹6.